Diagnostic and prognostic value of scavenger receptor class B type 1 in clear cell renal cell carcinoma

Tumor Biology

Volumn 39, Issue 5, 2017, Pages

  Xu, Guanghua ^a   Lou, Ning ^a   Xu, Yuchen ^a   Shi, Hangchuan ^a   Ruan, Hailong ^a   Xiao, Wen ^a   Liu, Lei ^a   Xiao, Haibing ^a   Qiu, Bin ^a   Bao, Lin ^a   Yuan, Changfei ^a   Chen, Ke ^a   Yang, Hongmei ^a   Zhang, Xiaoping ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Clear cell renal cell carcinoma; Diagnostic value; Prognostic value; Scavenger receptor class B type 1

Indexed keywords

MESSENGER RNA; SCAVENGER RECEPTOR BI; SCARB1 PROTEIN, HUMAN; SCAVENGER RECEPTOR B; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER SURGERY; CANCER TISSUE; CLINICAL OUTCOME; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RENAL CANCER CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; WESTERN BLOTTING; BIOSYNTHESIS; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; SCAVENGER RECEPTORS, CLASS B;

EID: 85020049247     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1177/1010428317699110     Document Type: Article

References (28)

1. Rini BI, Campbell SC and Escudier B. Renal cell carcinoma. Lancet 2009; 373: 1119-1132.
2. Oosterwijk E, Rathmell WK, Junker K, et al. Basic research in kidney cancer. Eur Urol 2011; 60: 622-633.
3. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
4. Lam JS, Leppert JT, Belldegrun AS, et al. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005; 23: 202-212.
5. Grimm M-O, Wolff I, Zastrow S, et al. Advances in renal cell carcinoma treatment. Ther Adv Urol 2010; 2: 11-17.
6. Zanoni P, Khetarpal SA, Larach DB, et al. Rare variant in scavenger receptor B1 raises HDL cholesterol and increases risk of coronary heart disease. Science 2016; 351(6278): 1166-1171.
7. Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457: 882-886.
8. Dorner M, Horwitz JA, Robbins JB, et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011; 474: 208-211.
9. Khan AG, Whidby J, Miller MT, et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 2014; 509: 381-384.
10. Danilo C, Gutierrez-Pajares JL, Mainieri MA, et al. Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development. Breast Cancer Res 2013; 15: R87.
11. de Gonzalo-Calvo D, Lopez-Vilaro L, Nasarre L, et al. Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study. BMC Cancer 2015; 15: 460.
12. Yuan B, Wu C, Wang X, et al. High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancer. Tumour Biol 2016; 37: 3581-3588.
13. Twiddy AL, Cox ME and Wasan KM. Knockdown of scavenger receptor class B type I reduces prostate specific antigen secretion and viability of prostate cancer cells. Prostate 2012; 72: 955-965.
14. Schorghofer D, Kinslechner K, Preitschopf A, et al. The HDL receptor SR-B1 is associated with human prostate cancer progression and plays a possible role in establishing androgen independence. Reprod Biol Endocrin 2015; 13: 88.
15. Zheng Y, Liu Y, Jin H, et al. Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles. Theranostics 2013; 3: 477-486.
16. Chen X, Wang X, Ruan A, et al. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res 2014; 20: 2617-2630.
17. Xu S, Tao Z, Hai B, et al. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun 2016; 7: 11406.
18. Yang H, Chen X, Wang X, et al. Inhibition of PP2A activity confers a TRAIL-sensitive phenotype during malignant transformation. Mol Cancer Res 2014; 12: 217-227.
19. Wang T, Song W, Chen Y, et al. Flightless I homolog represses prostate cancer progression through targeting androgen receptor signaling. Clin Cancer Res 2016; 22: 1531-1544.
20. Hsu PP and Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134: 703-707.
21. Upadhyay M, Samal J, Kandpal M, et al. The Warburg effect: insights from the past decade. Pharmacol Ther 2013; 137: 318-330.
22. Cao WM, Murao K, Imachi H, et al. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res 2004; 64: 1515-1521.
23. Fruhwurth S, Krieger S, Winter K, et al. Inhibition of mTOR down-regulates scavenger receptor, class B, type 1 (SR-B1) expression, reduces endothelial cell migration and impairs nitric oxide production. Biochim Biophys Acta 2014; 1841: 944-953.
24. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-B1 activates endothelial nitric oxide synthase. Nat Med 2001; 7: 853-857.
25. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res 2006; 12: 1201-1207.
26. Fukumura D, Kashiwagi S and Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6: 521-534.
27. Lahdenranta J, Hagendoorn J, Padera TP, et al. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res 2009; 69: 2801-2808.
28. Loibl S, Strank C, von Minckwitz G, et al. Immunohistochemical evaluation of endothelial nitric oxide synthase expression in primary breast cancer. Breast 2005; 14: 230-235.